Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 12:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,004 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Anti-bacterial Agents Clear all
Recruiting Phase 4 Interventional

Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

NCT07376889
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,096 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Brighton, Colorado • Denver, Colorado • Grand Junction, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 12:22 AM EDT
Completed Phase 3 Interventional

Control of Periodontal Infections

NCT01098448
View directory record Official record
Conditions
Periodontitis
Interventions
scaling and root planing, local tetracycline, systemic metronidazole and amoxicillin, surgery, local antibiotics and systemic metronidazole and amoxicillin, local tetracycline and periodontal surgery, periodontal surgery and systemic metronidazole and amoxicillin, surgery, local tetracycline, systemic metronidazole and amoxicillin
Other · Drug
Lead sponsor
The Forsyth Institute
Other
Eligibility
20 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 15, 2026, 12:22 AM EDT
Completed No phase listed Observational

Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis

NCT00304889
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 15, 2026, 12:22 AM EDT
Completed No phase listed Observational

Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea

NCT00304876
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2010 · Synced Oct 15, 2026, 12:22 AM EDT
Completed No phase listed Observational

PuraPly™ Antimicrobial Wound Matrix and Wound Management

NCT03070938
View directory record Official record
Conditions
Pressure Ulcer, Venous Ulcer, Diabetic Ulcer, Surgical Wound, Trauma Wound
Interventions
PuraPly™ Antimicrobial Wound Matrix
Device
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 15, 2026, 12:22 AM EDT
Completed Not applicable Interventional Results available

Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis (Antibiotics Alone vs. Appendectomy)

NCT02110485
View directory record Official record
Conditions
Appendicitis, Children
Interventions
Patient Activation Tool
Other
Lead sponsor
Peter Minneci
Other
Eligibility
7 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 15, 2026, 12:22 AM EDT
Not yet recruiting No phase listed Observational

Retrospective Kinetic Safety Evaluation of an Intravenous Micellar Excipient Platform

NCT07609069
View directory record Official record
Conditions
Drug Related Side Effects and Adverse Reactions, Infusion Reactions
Interventions
PIV-850 (850-picometer Dual-NCE Acidic Matrix), Legacy Heterogeneous Payload (Micellar Vehicle)
Drug
Lead sponsor
PICO IV, Inc.
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 15, 2026, 12:22 AM EDT
Enrolling by invitation Phase 3 Interventional

Antibiotic Prophylaxis in Rhinoplasty

NCT04194216
View directory record Official record
Conditions
Nasal Obstruction, Nasal Surgical Procedures
Interventions
Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg., Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 15, 2026, 12:22 AM EDT
Withdrawn Not applicable Interventional

Topical Antibiotic Use In Chronic Rhinosinusitis A Double-Blinded, Randomized, Placebo Controlled Study

NCT00669799
View directory record Official record
Conditions
Rhinosinusitis
Interventions
gentamyacin
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 15, 2026, 12:22 AM EDT
Completed Phase 2 Interventional Results available

The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"

NCT01595529
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Cefixime, Cephalexin, Placebo, Trimethoprim/Sulfamethoxazole
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 10 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 15, 2026, 12:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Impact of Irrisept in Reducing Urinary Tract Infection During Urethral Catheter Removal.

NCT07239219
View directory record Official record
Conditions
Urinary Tract Infection, Antibiotic, Catheter Infection
Interventions
0.05% Chlorhexidine Gluconate, Normal Saline
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 15, 2026, 12:22 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Nutraceutical Efficacy for rUTI

NCT03395288
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
D-Mannose
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 15, 2026, 12:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Merck IISP Stewardship Grant for Antibiotic Best Practices

NCT01573195
View directory record Official record
Conditions
Antibiotic Resistant Infection
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
1,285 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 15, 2026, 12:22 AM EDT
Completed Phase 2 Interventional Results available

Antibiotic Treatment Trial for the PANDAS/PANS Phenotype

NCT01617083
View directory record Official record
Conditions
PANS, PANDAS, Obsessive Compulsive Disorder (OCD)
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
4 Years to 14 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 15, 2026, 12:22 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.

NCT04126031
View directory record Official record
Conditions
Gram-negative Bacterial Infection
Interventions
Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3, Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Days to 88 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 15, 2026, 12:22 AM EDT
Completed Not applicable Interventional

Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial

NCT00100386
View directory record Official record
Conditions
Bacterial Diseases
Interventions
Intensive Control Strategy, Standard Control Strategy
Procedure · Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 15, 2026, 12:22 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Procalcitonin Protocol Use to Guide Antibiotic Therapy Duration in the Intensive Care Unit

NCT05756049
View directory record Official record
Conditions
Comparing Antibiotic Duration of Therapy
Interventions
compare antibiotic duration of therapy
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 15, 2026, 12:22 AM EDT
Completed No phase listed Observational

Decreasing Antibiotic Use in Infants With Suspected Ventilator-associated Infection

NCT03041207
View directory record Official record
Conditions
Ventilator Associated Pneumonia, Nosocomial Infections in Children, Microbial Colonization
Interventions
Development and implementation of an antibiotic guideline
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Up to 3 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 15, 2026, 12:22 AM EDT
Terminated Phase 3 Interventional

Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU

NCT00307099
View directory record Official record
Conditions
Bacterial Infection
Interventions
Meropenem, Standard antibiotic therapy
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Newark, Delaware • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2013 · Synced Oct 15, 2026, 12:22 AM EDT
Completed Not applicable Interventional Results available

Surgical Site Infection With 0.05% Chlorhexidine (CHG) Compared to Triple Antibiotic Irrigation

NCT02395614
View directory record Official record
Conditions
Breast Cancer
Interventions
Chlorhexidine irrigation, triple antibiotic irrigation
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 81 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 15, 2026, 12:22 AM EDT
Not yet recruiting Not applicable Interventional

Empowerment Program to Reduce Treatment of Asymptomatic Bacteriuria in Veterans With Spinal Cord Injury

NCT07430904
View directory record Official record
Conditions
Spinal Cord Injury, Spinal Cord Disease
Interventions
Empowerment Program
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 15, 2026, 12:22 AM EDT
Completed Phase 4 Interventional Results available

Antibiotic Resistance In Eye Surgeries

NCT04750655
View directory record Official record
Conditions
Antibiotic Resistance, Ocular Surface Microbiome, Gut Resistome
Interventions
Moxifloxacin (Topical)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 15, 2026, 12:22 AM EDT
Completed Not applicable Interventional

Appendectomy Versus Non-Operative Treatment For Acute Non-Perforated Appendicitis in Children

NCT02687464
View directory record Official record
Conditions
Appendicitis
Interventions
Non-operative treatment, Appendectomy
Other · Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
5 Years to 16 Years
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 15, 2026, 12:22 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06411899
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Sonelokimab, Placebo
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
36
States / cities
Los Angeles, California • Northridge, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 15, 2026, 12:22 AM EDT